Skip to main content
PMC home page
Mediators of Inflammation logoLink to Mediators of Inflammation
. 1996 Jun;5(3):196–201. doi: 10.1155/S0962935196000270

Inhibition of the activity of pro-inflammatory secretory phospholipase A2 by acute phase proteins

W Pruzanski 1,✉, E Stefanski 1, P Vadas 1
PMCID: PMC2365793  PMID: 18475716

Abstract

Pro-Inflammatory non-pancreatic phospholipase A2 (sPLA2) is markedly over-expressed in acute systemic and chronic local inflammatory processes. Since in acute phase reaction sPLA2 is often over-expressed simultaneously with acute phase proteins (APP), it is important to determine whether APP interacts with sPLA2. We tested ten APPs for interaction with sPLA2 using as a substrate multilamellar Hposomes composed either of PC:Lyso PC or PE:Lyso PE. Using PC:Lyso PC substrate, CRP, lactoferrin and SAP were found to inhibit sPLA2 activity with an IC50 of 25 μg/ml, 7.5 μg/ml and 50 μg/ml, respectively, corresponding to 0.21 μM, 0.1 μM and 0.21 μM respectively. Using PE:Lyso PE substrate only SAP was inhibitory, with an IC50 of 10 μg/ml (0.04 μM). Phosphorylcholine abolished the inhibitory activity of CRP but not of SAP or lactoferrin. Addition of phosphorylethanolamine or of excess calcium had no effect on the inhibitory activity of APP. Limulin, lysozyme, transferrin, β2-microglobulin, α2-macroglobulin, human and bovine albumins had no effect on sPLA2 activity. Therefore neither the structure of pentraxins, or ironbinding, bacteriostatic property or amyloidogenic property preclude whether APP modulates sPLA2 activity. Inhibition of pro-inflammatory sPLA2 by APP may be one of the protective mechanisms of the acute phase reaction.

Full Text

The Full Text of this article is available as a PDF (612.5 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baumann H., Gauldie J. The acute phase response. Immunol Today. 1994 Feb;15(2):74–80. doi: 10.1016/0167-5699(94)90137-6. [DOI] [PubMed] [Google Scholar]
  2. Bomalaski J. S., Clark M. A. Phospholipase A2 and arthritis. Arthritis Rheum. 1993 Feb;36(2):190–198. doi: 10.1002/art.1780360208. [DOI] [PubMed] [Google Scholar]
  3. Cohen M. S., Mao J., Rasmussen G. T., Serody J. S., Britigan B. E. Interaction of lactoferrin and lipopolysaccharide (LPS): effects on the antioxidant property of lactoferrin and the ability of LPS to prime human neutrophils for enhanced superoxide formation. J Infect Dis. 1992 Dec;166(6):1375–1378. doi: 10.1093/infdis/166.6.1375. [DOI] [PubMed] [Google Scholar]
  4. Courtoy P. J., Lombart C., Feldmann G., Moguilevsky N., Rogier E. Synchronous increase of four acute phase proteins synthesized by the same hepatocytes during the inflammatory reaction: a combined biochemical and morphologic kinetics study in the rat. Lab Invest. 1981 Feb;44(2):105–115. [PubMed] [Google Scholar]
  5. Crowl R. M., Stoller T. J., Conroy R. R., Stoner C. R. Induction of phospholipase A2 gene expression in human hepatoma cells by mediators of the acute phase response. J Biol Chem. 1991 Feb 5;266(4):2647–2651. [PubMed] [Google Scholar]
  6. Dennis E. A. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem. 1994 May 6;269(18):13057–13060. [PubMed] [Google Scholar]
  7. Dowton S. B., Colten H. R. Acute phase reactants in inflammation and infection. Semin Hematol. 1988 Apr;25(2):84–90. [PubMed] [Google Scholar]
  8. Ellison R. T., 3rd, Giehl T. J. Killing of gram-negative bacteria by lactoferrin and lysozyme. J Clin Invest. 1991 Oct;88(4):1080–1091. doi: 10.1172/JCI115407. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Franson R., Dobrow R., Weiss J., Elsbach P., Weglicki W. B. Isolation and characterization of a phospholipase A2 from an inflammatory exudate. J Lipid Res. 1978 Jan;19(1):18–23. [PubMed] [Google Scholar]
  10. Goulding N. J., Guyre P. M. Glucocorticoids, lipocortins and the immune response. Curr Opin Immunol. 1993 Feb;5(1):108–113. doi: 10.1016/0952-7915(93)90089-b. [DOI] [PubMed] [Google Scholar]
  11. Gutteberg T. J., Røkke O., Andersen O., Jørgensen T. Early fall of circulating iron and rapid rise of lactoferrin in septicemia and endotoxemia: an early defence mechanism. Scand J Infect Dis. 1989;21(6):709–715. doi: 10.3109/00365548909021701. [DOI] [PubMed] [Google Scholar]
  12. Harwig S. S., Tan L., Qu X. D., Cho Y., Eisenhauer P. B., Lehrer R. I. Bactericidal properties of murine intestinal phospholipase A2. J Clin Invest. 1995 Feb;95(2):603–610. doi: 10.1172/JCI117704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990 Feb 1;265(3):621–636. doi: 10.1042/bj2650621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kennedy B. P., Payette P., Mudgett J., Vadas P., Pruzanski W., Kwan M., Tang C., Rancourt D. E., Cromlish W. A. A natural disruption of the secretory group II phospholipase A2 gene in inbred mouse strains. J Biol Chem. 1995 Sep 22;270(38):22378–22385. doi: 10.1074/jbc.270.38.22378. [DOI] [PubMed] [Google Scholar]
  15. MacPhee M., Chepenik K. P., Liddell R. A., Nelson K. K., Siracusa L. D., Buchberg A. M. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia. Cell. 1995 Jun 16;81(6):957–966. doi: 10.1016/0092-8674(95)90015-2. [DOI] [PubMed] [Google Scholar]
  16. Nagpurkar A., Saxena U., Mookerjea S. Interaction of rat serum phosphorylcholine-binding protein with phospholipid-containing liposomes. J Biol Chem. 1983 Sep 10;258(17):10518–10523. [PubMed] [Google Scholar]
  17. Nguyen N. Y., Suzuki A., Cheng S. M., Zon G., Liu T. Y. Isolation and characterization of Limulus C-reactive protein genes. J Biol Chem. 1986 Aug 5;261(22):10450–10455. [PubMed] [Google Scholar]
  18. Nuijens J. H., Abbink J. J., Wachtfogel Y. T., Colman R. W., Eerenberg A. J., Dors D., Kamp A. J., Strack van Schijndel R. J., Thijs L. G., Hack C. E. Plasma elastase alpha 1-antitrypsin and lactoferrin in sepsis: evidence for neutrophils as mediators in fatal sepsis. J Lab Clin Med. 1992 Feb;119(2):159–168. [PubMed] [Google Scholar]
  19. Pruzanski W., Vadas P., Fornasier V. Inflammatory effect of intradermal administration of soluble phospholipase A2 in rabbits. J Invest Dermatol. 1986 Apr;86(4):380–383. doi: 10.1111/1523-1747.ep12285639. [DOI] [PubMed] [Google Scholar]
  20. Pruzanski W., de Beer F. C., de Beer M. C., Stefanski E., Vadas P. Serum amyloid A protein enhances the activity of secretory non-pancreatic phospholipase A2. Biochem J. 1995 Jul 15;309(Pt 2):461–464. doi: 10.1042/bj3090461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Ramadori G., Sipe J. D., Dinarello C. A., Mizel S. B., Colten H. R. Pretranslational modulation of acute phase hepatic protein synthesis by murine recombinant interleukin 1 (IL-1) and purified human IL-1. J Exp Med. 1985 Sep 1;162(3):930–942. doi: 10.1084/jem.162.3.930. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Richards C., Gauldie J., Baumann H. Cytokine control of acute phase protein expression. Eur Cytokine Netw. 1991 Mar-Apr;2(2):89–98. [PubMed] [Google Scholar]
  23. Robey F. A., Liu T. Y. Limulin: a C-reactive protein from Limulus polyphemus. J Biol Chem. 1981 Jan 25;256(2):969–975. [PubMed] [Google Scholar]
  24. Schultz D. R., Arnold P. I. Properties of four acute phase proteins: C-reactive protein, serum amyloid A protein, alpha 1-acid glycoprotein, and fibrinogen. Semin Arthritis Rheum. 1990 Dec;20(3):129–147. doi: 10.1016/0049-0172(90)90055-k. [DOI] [PubMed] [Google Scholar]
  25. Schwalbe R. A., Dahlbäck B., Coe J. E., Nelsestuen G. L. Pentraxin family of proteins interact specifically with phosphorylcholine and/or phosphorylethanolamine. Biochemistry. 1992 May 26;31(20):4907–4915. doi: 10.1021/bi00135a023. [DOI] [PubMed] [Google Scholar]
  26. Steel D. M., Whitehead A. S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol Today. 1994 Feb;15(2):81–88. doi: 10.1016/0167-5699(94)90138-4. [DOI] [PubMed] [Google Scholar]
  27. Suwa Y., Kudo I., Imaizumi A., Okada M., Kamimura T., Suzuki Y., Chang H. W., Hara S., Inoue K. Proteinaceous inhibitors of phospholipase A2 purified from inflammatory sites in rats. Proc Natl Acad Sci U S A. 1990 Apr;87(7):2395–2399. doi: 10.1073/pnas.87.7.2395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Swanson S. J., Christner R. B., Mortensen R. F. Human serum amyloid P-component (SAP) selectively binds to immobilized or bound forms of C-reactive protein (CRP). Biochim Biophys Acta. 1992 Dec 28;1160(3):309–316. doi: 10.1016/0167-4838(92)90093-s. [DOI] [PubMed] [Google Scholar]
  29. Tennent G. A., Butler P. J., Hutton T., Woolfitt A. R., Harvey D. J., Rademacher T. W., Pepys M. B. Molecular characterization of Limulus polyphemus C-reactive protein. I. Subunit composition. Eur J Biochem. 1993 May 15;214(1):91–97. doi: 10.1111/j.1432-1033.1993.tb17900.x. [DOI] [PubMed] [Google Scholar]
  30. Vadas P., Browning J., Edelson J., Pruzanski W. Extracellular phospholipase A2 expression and inflammation: the relationship with associated disease states. J Lipid Mediat. 1993 Aug;8(1):1–30. [PubMed] [Google Scholar]
  31. Vadas P., Pruzanski W. Induction of group II phospholipase A2 expression and pathogenesis of the sepsis syndrome. Circ Shock. 1993 Feb;39(2):160–167. [PubMed] [Google Scholar]
  32. Vadas P., Pruzanski W., Stefanski E., Ellies L. G., Aubin J. E., Sos A., Melcher A. Extracellular phospholipase A2 secretion is a common effector pathway of interleukin-1 and tumour necrosis factor action. Immunol Lett. 1991 Jun;28(3):187–193. doi: 10.1016/0165-2478(91)90002-r. [DOI] [PubMed] [Google Scholar]
  33. Vadas P., Pruzanski W., Stefanski E., Sternby B., Mustard R., Bohnen J., Fraser I., Farewell V., Bombardier C. Pathogenesis of hypotension in septic shock: correlation of circulating phospholipase A2 levels with circulatory collapse. Crit Care Med. 1988 Jan;16(1):1–7. doi: 10.1097/00003246-198801000-00001. [DOI] [PubMed] [Google Scholar]
  34. Vadas P., Schouten B. D., Stefanski E., Scott K., Pruzanski W. Association of hyperphospholipasemia A2 with multiple system organ dysfunction due to salicylate intoxication. Crit Care Med. 1993 Jul;21(7):1087–1091. doi: 10.1097/00003246-199307000-00027. [DOI] [PubMed] [Google Scholar]
  35. Vadas P., Stefanski E., Grouix B., Schouten B. D., Pruzanski W. Inhibition of human group II phospholipase A2 by C-reactive protein in vitro. J Lipid Mediat Cell Signal. 1995 Mar;11(2):187–200. doi: 10.1016/0929-7855(94)00037-d. [DOI] [PubMed] [Google Scholar]
  36. Vadas P., Taylor T. E., Chimsuku L., Goldring D., Stefanski E., Pruzanski W., Molyneux M. E. Increased serum phospholipase A2 activity in Malawian children with falciparum malaria. Am J Trop Med Hyg. 1993 Oct;49(4):455–459. doi: 10.4269/ajtmh.1993.49.455. [DOI] [PubMed] [Google Scholar]
  37. Vadas P., Wasi S., Movat H. Z., Hay J. B. A novel, vasoactive product and plasminogen activator from afferent lymph cells draining chronic inflammatory lesions. Proc Soc Exp Biol Med. 1979 May;161(1):82–85. doi: 10.3181/00379727-161-40495. [DOI] [PubMed] [Google Scholar]
  38. Wright G. W., Ooi C. E., Weiss J., Elsbach P. Purification of a cellular (granulocyte) and an extracellular (serum) phospholipase A2 that participate in the destruction of Escherichia coli in a rabbit inflammatory exudate. J Biol Chem. 1990 Apr 25;265(12):6675–6681. [PubMed] [Google Scholar]
  39. Ying S. C., Marchalonis J. J., Gewurz A. T., Siegel J. N., Jiang H., Gewurz B. E., Gewurz H. Reactivity of anti-human C-reactive protein (CRP) and serum amyloid P component (SAP) monoclonal antibodies with limulin and pentraxins of other species. Immunology. 1992 Jun;76(2):324–330. [PMC free article] [PubMed] [Google Scholar]
  40. Zagulski T., Lipiński P., Zagulska A., Broniek S., Jarzabek Z. Lactoferrin can protect mice against a lethal dose of Escherichia coli in experimental infection in vivo. Br J Exp Pathol. 1989 Dec;70(6):697–704. [PMC free article] [PubMed] [Google Scholar]

Articles from Mediators of Inflammation are provided here courtesy of Wiley

RESOURCES